Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2019

View Archived Issues

LNC Therapeutics and INRA enter partnership to study anti-inflammatory properties of gut microbiome

Phase II trials of concizumab show clinical proof of concept for bleeding prevention in hemophilia

BET inhibitor JQ1(+) can be repurposed for lymphatic filariasis, new transcriptomics study suggests

Biogen discontinues development of gosuranemab for progressive supranuclear palsy

Phase II results for vasopressin V1B receptor antagonist TS-121 in MDD

Results reported from ongoing phase I study of FT-4202

ARX-788 well-tolerated in phase I study in Chinese patients with metastatic HER2+ breast cancer

Cirmtuzumab plus paclitaxel safe and well-tolerated in phase I study in breast cancer

Blood-brain barrier disruption could be Alzheimer's target

GDF1 unveiled as a therapeutic target for treating AML

Unexpected Ibrance MOA

Shanghai Zhimeng Biopharma describes potassium channel activators

Beijing Innocare Pharmaceutical Technology discovers IDO-1 inhibitors

Decoding EGFR's skin toxicity

New AXL/c-Met inhibitors disclosed by Shanghai Institute of Materia Medica

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent estrogen receptor antagonists

New PI3Kgamma/PI3Kdelta inhibitors synthesized at Incyte

Chitotriosidase-1 levels rise prior to onset of ALS symptoms

FDA approves Vascepa to reduce cardiovascular risk in adults with elevated triglyceride levels

LUSTER-1 and -2 results do not support further development of fevipiprant in asthma

MHRA clears initiation of phase I trial of brilacidin delayed-release tablets

Funding supports Synedgen's optimization of therapies to restore GI integrity in IBD

Ustekinumab biosimilar DMB-3115 begins phase I trial

Basilea to advance lisavanbulin development with biomarker-driven study

Wave Life Sciences discontinues development of suvodirsen for DMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...